Mangrove Partners IM LLC Acquires New Holdings in Elevance Health, Inc. $ELV

Mangrove Partners IM LLC bought a new position in shares of Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 5,918 shares of the company’s stock, valued at approximately $1,912,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Nilsine Partners LLC boosted its holdings in shares of Elevance Health by 1.5% in the third quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after buying an additional 29 shares during the period. HBK Sorce Advisory LLC raised its holdings in shares of Elevance Health by 4.4% during the third quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock worth $260,000 after acquiring an additional 31 shares during the period. Detalus Advisors LLC raised its holdings in shares of Elevance Health by 1.8% during the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after acquiring an additional 31 shares during the period. Forum Financial Management LP lifted its position in Elevance Health by 1.1% in the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock valued at $960,000 after acquiring an additional 33 shares in the last quarter. Finally, Activest Wealth Management lifted its position in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Analyst Ratings Changes

ELV has been the subject of a number of research reports. Jefferies Financial Group lowered their target price on Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a report on Friday, January 30th. Morgan Stanley reduced their price objective on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. UBS Group set a $400.00 price objective on Elevance Health in a report on Thursday, January 29th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research report on Thursday, January 29th. Finally, JPMorgan Chase & Co. boosted their target price on Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Twelve research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Elevance Health has an average rating of “Moderate Buy” and an average price target of $387.40.

Elevance Health Stock Up 1.3%

ELV stock opened at $291.69 on Friday. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The business’s 50 day simple moving average is $338.25 and its 200 day simple moving average is $334.11. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $64.38 billion, a PE ratio of 11.61, a PEG ratio of 1.59 and a beta of 0.51.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. During the same quarter in the previous year, the firm posted $3.84 EPS. Elevance Health’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is presently 27.39%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.